Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? (Q90682666)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31608320 AND SRC:MED&resulttype=core&format=json

15 April 2020

title

Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31608320 AND SRC:MED&resulttype=core&format=json

15 April 2020

author name string

Chen Zhao

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31608320 AND SRC:MED&resulttype=core&format=json

15 April 2020

Arun Rajan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31608320 AND SRC:MED&resulttype=core&format=json

15 April 2020

publication date

9 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31608320 AND SRC:MED&resulttype=core&format=json

15 April 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31608320 AND SRC:MED&resulttype=core&format=json

A case report of giant cell myocarditis and myositis observed during the clinical course of invasive thymoma associated with myasthenia gravis.

15 April 2020

cites work

1 reference

12 December 2020

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

1 reference

12 December 2020

Treatment of advanced thymoma and thymic carcinoma.

1 reference

12 December 2020

Thymoma and paraneoplastic myasthenia gravis

1 reference

12 December 2020

Fulminant giant cell myocarditis and cardiogenic shock: an unusual presentation of malignant thymoma

1 reference

12 December 2020

Epidemiology of Thymoma and Associated Malignancies

1 reference

12 December 2020

Aire and T cell development

1 reference

12 December 2020

The etiology of paraneoplastic autoimmunity

1 reference

12 December 2020

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors

1 reference

12 December 2020

Thymic malignancies: from clinical management to targeted therapies

1 reference

12 December 2020

Case records of the Massachusetts General Hospital. Case 39-2011. A woman in her 90s with unilateral ptosis

1 reference

12 December 2020

The blockade of immune checkpoints in cancer immunotherapy

1 reference

12 December 2020

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors

1 reference

12 December 2020

Giant cell polymyositis and myocarditis associated with myasthenia gravis and thymoma

1 reference

12 December 2020

What lies within: novel strategies in immunotherapy for non-small cell lung cancer

1 reference

12 December 2020

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

1 reference

12 December 2020

Novel biologic therapies for thymic epithelial tumors

1 reference

12 December 2020

Alterations of the immune system in thymic malignancies

1 reference

12 December 2020

Diffuse high intensity PD-L1 staining in thymic epithelial tumors

1 reference

12 December 2020

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

12 December 2020

A survival case of invasive thymoma accompanied by acute fulminant myocarditis

1 reference

12 December 2020

Mutations of epigenetic regulatory genes are common in thymic carcinomas

1 reference

12 December 2020

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

1 reference

12 December 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

12 December 2020

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.

1 reference

12 December 2020

Giant cell myositis responsive to combined corticosteroids and immunoglobulin

1 reference

12 December 2020

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart

1 reference

12 December 2020

Thymoma associated with autoimmune diseases: 85 cases and literature review.

1 reference

12 December 2020

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

1 reference

12 December 2020

1 reference

12 December 2020

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

1 reference

12 December 2020

Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy

1 reference

12 December 2020

CANCER IMMUNOLOGY. The "cancer immunogram".

1 reference

12 December 2020

Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.

1 reference

12 December 2020

Review of the mechanisms involved in the abscopal effect and future directions with a focus on thymic carcinoma.

1 reference

12 December 2020

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

1 reference

12 December 2020

Is autoimmunity the Achilles' heel of cancer immunotherapy?

1 reference

12 December 2020

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.

1 reference

12 December 2020

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

1 reference

12 December 2020

Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.

1 reference

12 December 2020

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

1 reference

12 December 2020

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

1 reference

12 December 2020

WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.

1 reference

12 December 2020

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

1 reference

12 December 2020

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

1 reference

12 December 2020

Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead

1 reference

12 December 2020

The Integrated Genomic Landscape of Thymic Epithelial Tumors

1 reference

12 December 2020

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

1 reference

12 December 2020

Cancer immunotherapy using checkpoint blockade.

1 reference

12 December 2020

Defining and Understanding Adaptive Resistance in Cancer Immunotherapy

1 reference

12 December 2020

Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process?

1 reference

12 December 2020

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

1 reference

12 December 2020

Thymic tolerance as a key brake on autoimmunity.

1 reference

12 December 2020

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

1 reference

12 December 2020

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

1 reference

12 December 2020

Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

1 reference

12 December 2020

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

1 reference

12 December 2020

Immune checkpoint inhibitor rechallenge in patients with immune-related myositis

1 reference

12 December 2020

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

1 reference

12 December 2020

PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis

1 reference

12 December 2020

Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors

1 reference

12 December 2020

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy

1 reference

12 December 2020

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

1 reference

12 December 2020

WT1 as an immunotherapy target for thymic epithelial tumors: a novel method to activate anti-tumor immunity

1 reference

12 December 2020

Identifiers

DOI

10.21037/MED.2019.08.02

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31608320 AND SRC:MED&resulttype=core&format=json

15 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31608320 AND SRC:MED&resulttype=core&format=json

15 April 2020

PubMed publication ID

31608320

1 reference